942145-27-9

Basic information

• Product Name: CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester
• CAS NO: 942145-27-9
• Molecular Formula: C₁₄H₂₈N₂O₃
• Molecular Weight: 272.38372
• Mol File: 942145-27-9.mol

Chemical Properties

• Boiling Point: 370.2°C at 760 mmHg
• Flash Point: 177.7°C
• Appearance: /
• Density: 1.026g/cm³
• Vapor Pressure: 1.13E-05mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester(942145-27-9)
• EPA Substance Registry System: CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester(942145-27-9)

Safety Data

• Hazardous Substances Data: 942145-27-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester is used as a prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is utilized for its ability to release d-amphetamine, which helps in managing the symptoms of these conditions by enhancing focus and alertness.
Used in Research and Development:
In the field of neuroscience and pharmaceutical research, CarbaMic acid, N-[(1S)-1-(aMinoMethyl)-2-[(3R)-tetrahydro-2H-pyran-3-yl]ethyl]-N-Methyl-, 1,1-diMethylethyl ester is used to study the effects of norepinephrine and dopamine release on cognitive function and alertness. This helps in understanding the mechanisms of action of stimulant medications and their potential applications in various neurological disorders.

InChI:InChI=1/C14H28N2O3/c1-14(2,3)19-13(17)16(4)12(9-15)8-11-6-5-7-18-10-11/h11-12H,5-10,15H2,1-4H3/t11-,12+/m1/s1

Upstream product

• 1093865-02-1 1,1-dimethylethyl methyl{2-({[(phenylmethyl)oxy]carbonyl}amino)-1-[(3R)-tetrahydro-2H-pyran-3-ylmethyl]ethyl}carbamate 
• 1013937-77-3 (R)-2-(3-chloro-propyl)-N-((1S,2S)-1-hydroxy-1-phenyl-propan-2-yl)-N-methyl-pent-4-enamide 
• 1093865-64-5 1,1-dimethylethyl {2-amino-1-[(3R)-tetrahydro-2H-pyran-3-ylmethyl]ethyl}methylcarbamate 
• 1013937-76-2 5-chloro-N-((1S,2S)-1-hydroxy-1-phenyl-propan-2-yl)-N-methyl-pentanamide 
• 1013937-78-4 (R)-2-(3-chloro-propyl)-pent-4-en-1-ol 
• 1013937-83-1 N-(2-((R)-tetrahydro-2H-pyran-3-yl)-eth-(E)-ylidene)methanamine 
• 1013937-79-5 (R)-3-allyl-tetrahydro-2H-pyran 
• 1013937-81-9 (R)-2-(tetrahydro-2H-pyran-3-yl)-acetaldehyde 
• 1575-61-7 5-Chlorovaleroyl chloride 
• 153080-81-0 (2S,4R)-1-tert-butyl 4-allyl-2-ethoxycarbonyl-5-oxopyrrolidine-1-carboxylate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 942145-24-6 tert-butyl (S)-1-azido-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamate 
• 942145-23-5 (S)-2-(tert-butoxycarbonylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propyl 4-methylbenzenesulfonate 
• 942144-43-6 tert-butyl (S)-1-hydroxy-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamate 

Downstream Products

• 1093865-45-2 methyl {2-[((R)-(3-chlorophenyl){3-[({(2S)-2-[{[(1,1-dimethylethyl)oxy]carbonyl}(methyl)amino]-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl}amino)carbonyl]phenyl}methyl)oxy]ethyl}carbamate 
• 1093865-51-0 [2-{3-[((S)-2-methoxycarbonylamino-ethoxy)-phenyl-methyl]-benzoylamino}-1-((R)-tetrahydro-pyran-3-ylmethyl)-ethyl]-methyl-carbamic acid tert-butyl ester 
• 1093865-57-6 [2-{3-[((S)-2-methoxycarbonylamino-ethoxy)-m-tolyl-methyl]-benzoylamino}-1-((R)-tetrahydropyran-3-ylmethyl)-ethyl]-methyl-carbamic acid tert-butyl ester 
• 1093865-63-4 [2-{3-[(3-chloro-5-fluoro-phenyl)-((S)-2-methoxycarbonylamino-ethoxy)-methyl]-benzoylamino}-1-((R)-tetrahydro-pyran-3-ylmethyl)-ethyl]-methyl-carbamic acid tert-butyl ester 
• 1013937-63-7 methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate trifluoroacetate 
• 1093864-75-5 methyl {2-[((R)-(3-chlorophenyl){3-[({(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl}amino)carbonyl]phenyl}methyl)oxy]ethyl}carbamate 

Relevant articles and documents

Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility

Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)

RENIN INHIBITORS AND METHOD OF USE THEREOF

Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1 , R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceut

PROCESS FOR THE PREPARATION OF RENIN INHIBITORS

Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.

RENIN INHIBITORS

Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.